Answers are grounded in this paper and cite their sources.
Review demonstrates pathway engineering of apoptosis and autophagy in tumor cells, suggesting multi-target biomarker-guided combinations overcome drug resistance.
Cancer is characterised by resistance to programmed cell death, and of the various known cell death mechanisms, apoptosis and autophagy continue to be the most well characterised and treatable. The molecular architecture of the intrinsic and extrinsic apoptotic pathways, the fundamental autophagy mechanism, and the complex communication network focused on mTOR signalling, BCL-2/Beclin-1 and p53 interactions that determine whether a stressed cell survives or dies are summarised in this review. We look at different methodologies for “engineering” pathways such as BH3 mimetics, epigenetic modulators, CRISPR/Cas9 and RNA interference-based gene editing and delivery systems which enabled by nanotechnology which is enabled the accurate, tumor-selective death induction. We also discuss the integration with synthetic lethality, immunotherapy, and artificial intelligence-driven drug discovery to tackle the specific characteristics of autophagy. Therapeutic agents such as venetoclax, temsirolimus, hydroxychloroquine, and everolimus are examples of potential therapeutic approaches but also have some drawbacks like resistance, delivery, and heterogeneity. Perhaps, we concluded that combination therapeutic approaches, which are biomarker-guided, multi-target, and locally targeted as compared to single pathway modalities, are the future of programmed cell death engineering.
No takes yet. Share an insight, caveat, or question.
Pratik Umesh Parikh1*, Dr. Gunjan Jadon2, Dr. Vipul Patel3, Dr. P K Choudhary4, Dr. Awadh Kishor5, Rushikesh Mohite6, Sakshi Kapure6, Lahu Tandale6 (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: